Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

ClinicalTrials.gov ID: NCT02581865

Public ClinicalTrials.gov record NCT02581865. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Adult Subjects With Tourette Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment. This study will enroll approximately 90 male and female subjects clinically diagnosed with Tourette Syndrome.

Study identification

NCT ID: NCT02581865
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Neurocrine Biosciences; Industry
Enrollment: 124 participants

Conditions and interventions

Conditions

Tourette Syndrome

Interventions

NBI-98854 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 64 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2015 (Actual)
Primary completion: Dec 2016 (Actual)
Completion: Dec 2016 (Actual)
Last update posted: May 7, 2020

2015 – 2016

United States locations

U.S. sites: 30
U.S. states: 16
U.S. cities: 30

Facility	City	State	ZIP	Site status
Not listed	Long Beach	California	—	—
Not listed	National City	California	—	—
Not listed	San Bernardino	California	—	—
Not listed	San Diego	California	—	—
Not listed	Upland	California	—	—
Not listed	Gainesville	Florida	—	—
Not listed	Hialeah	Florida	—	—
Not listed	St. Petersburg	Florida	—	—
Not listed	Tampa	Florida	—	—
Not listed	Atlanta	Georgia	—	—
Not listed	Chicago	Illinois	—	—
Not listed	Boston	Massachusetts	—	—
Not listed	Natick	Massachusetts	—	—
Not listed	St Louis	Missouri	—	—
Not listed	Nashua	New Hampshire	—	—
Not listed	Summit	New Jersey	—	—
Not listed	Albany	New York	—	—
Not listed	Manhasset	New York	—	—
Not listed	New York	New York	—	—
Not listed	Staten Island	New York	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Oklahoma City	Oklahoma	—	—
Not listed	Norristown	Pennsylvania	—	—
Not listed	Nashville	Tennessee	—	—
Not listed	Dallas	Texas	—	—
Not listed	Irving	Texas	—	—
Not listed	Orem	Utah	—	—
Not listed	Salt Lake City	Utah	—	—
Not listed	Kirkland	Washington	—	—
Not listed	Spokane	Washington	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02581865, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 7, 2020 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02581865 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →